Intellectual Property India Publishes Patent Application for 'Anti-Tnfr2 Antigen-Binding Proteins And Uses Thereof' Filed by Odyssey Therapeutics, Inc.

MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517062596 A) filed by Odyssey Therapeutics, Inc., Boston, on July 1, for 'anti-tnfr2 antigen-binding proteins and uses thereof.'

Inventor(s) include Franchi, Luigi; Opipari, Anthony, W.; Swee, Lee, Kim; Konig, Paul-Albert; Preiss, Laura; Huber, Ferdinand; Seifried, Annegrit; Knopf, Julia; and Prochnicki, Tomasz.

The application for the patent was published on July 25, under issue no. 30/2025.

According to the abstract released by the Intellectual Property India: "The present application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind tumor necrosis factor receptor 2 (TNFR2). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins and methods for treating a disease or disorder using the antigen-binding proteins."

The patent application was internationally filed on Jan. 08, 2024, under International application No.PCT/US2024/010660.

Disclaimer: Curated by HT Syndication.